



**Sarupria Somani & Associates**  
**Chartered Accountants**

**Partner : CA Miral Bipinbhai Mehta**  
**B.Com, FCA**

**314, 3rd Floor, Imperial Arc,  
Opp. Shamaldas College Gate,  
Waghawadi Road, Bhavnagar.**  
**Tel.: 0278-2564366**  
**Mobile : 9909366366**  
**Email : somanibvn@gmail.com**

**Limited Review Report on standalone un-audited financial results for Quarterly and Nine Month ended on 31<sup>st</sup> December, 2023 of Par Drugs and Chemicals Limited under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015**

**To,**  
**The Board of Directors**  
**Par Drugs and Chemicals Limited**

We have reviewed the accompanying statement of unaudited financial results of **Par Drugs and Chemicals Limited** having its registered office at 815, Nilamber Triumph, Gotri Vasna Road, Vadodara, Gujarat-390007 for the quarter and nine month ended 31st December, 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



**Branches**

**Udaipur • Ahmedabad • Akola • Mumbai • Delhi • Singruli • Jaipur • Gandhinagar**  
**Rudrapur • Indore • Pune • Kolkata • Ghaziabad • Raipur • Shimla • Chandigarh**



**Sarupria Somani & Associates**  
**Chartered Accountants**

**Partner : CA Miral Bipinbhai Mehta**  
**B.Com, FCA**

**314, 3rd Floor, Imperial Arc,**  
**Opp. Shamaldas College Gate,**  
**Waghawadi Road, Bhavnagar.**  
**Tel.: 0278-2564366**  
**Mobile : 9909366366**  
**Email : somanibvn@gmail.com**

Our conclusion is not modified in respect of this matter.

SARUPRIA SOMANI & ASSOCIATES

(Firm Regn No. – 010674C)

CHARTERED ACCOUNTANTS

MIRAL MEHTA (Partner)

M.No.145361

Bhavnagar, 16<sup>th</sup> February, 2024

UDIN – 24145361BKFORD2642



**Branches**

**Udaipur • Ahmedabad • Akola • Mumbai • Delhi • Singruli • Jaipur • Gandhinagar**  
**Rudrapur • Indore • Pune • Kolkata • Ghaziabad • Raipur • Shimla • Chandigarh**

PAR DRUGS AND CHEMICALS LIMITED  
(CIN : L24117GJ1999PLC035512)


Registered Office : 815, Nilamber Triumph, Gotri Vasna Road, Vadodara-390007, Gujarat, India  
Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com Website: www.pardrugs.com  
Standalone Unaudited Financial Results for the Quarter and Nine Month Ended 31st December, 2023  
Statement Of Profit & Loss

(Rs. in Lakhs)

	Particulars	Quarter Ended			Year to Date		Year Ended
		31/12/2023	30/09/2023	31/12/2022	31/12/2023	31/12/2022	31/03/2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	Revenue from operations	2,399.91	2,588.73	2,293.27	7,282.12	7,125.72	9,574.88
II	Other income	22.91	4.91	3.77	29.03	20.68	23.83
III	<b>Total Revenue (I + II)</b>	<b>2,422.82</b>	<b>2,593.64</b>	<b>2,297.04</b>	<b>7,311.14</b>	<b>7,146.40</b>	<b>9,598.71</b>
IV	<b>Expenses:</b>						
	Cost of materials consumed	822.22	789.80	1,180.70	2,612.97	3,293.58	4,102.73
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00	0.00
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	-36.74	111.04	-154.78	40.44	-144.63	-70.23
	Employee benefits expense	143.16	116.77	133.93	372.21	333.04	488.79
	Finance costs	1.96	2.67	2.96	6.19	10.62	13.32
	Depreciation and amortization expense	86.53	84.78	74.25	254.42	238.53	323.32
	Other expenses	948.37	834.87	810.35	2,584.14	2,361.27	3,232.85
	<b>Total expenses (IV)</b>	<b>1,965.50</b>	<b>1,939.93</b>	<b>2,047.41</b>	<b>5,870.37</b>	<b>6,092.42</b>	<b>8,090.79</b>
V	<b>Profit / (loss) before exceptional items and tax (III-IV)</b>	<b>457.32</b>	<b>653.71</b>	<b>249.64</b>	<b>1,440.77</b>	<b>1,053.98</b>	<b>1,507.92</b>
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit / (loss) before tax (V - VI)</b>	<b>457.32</b>	<b>653.71</b>	<b>249.64</b>	<b>1,440.77</b>	<b>1,053.98</b>	<b>1,507.92</b>
VIII	<b>Tax expense:</b>						
	(1) Current tax	115.10	164.53	62.83	362.61	265.27	379.51
	(2) Deferred tax	0.00	0.00	0.00	0.00	0.00	-5.00
IX	<b>Profit / (Loss) for the period from continuing operations (VII-VIII)</b>	<b>342.22</b>	<b>489.18</b>	<b>186.80</b>	<b>1,078.16</b>	<b>788.71</b>	<b>1,133.41</b>
X	Profit / (loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	<b>Profit / (loss) from Discontinued operations (after tax) (X-XI)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
XIII	<b>Profit / (Loss) for the period (IX + XII)</b>	<b>342.22</b>	<b>489.18</b>	<b>186.80</b>	<b>1,078.16</b>	<b>788.71</b>	<b>1,133.41</b>
XIV	<b>Other Comprehensive Income</b>						
	A (i) items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	B (i) items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00
XV	<b>Total Comprehensive Income for the period (comprising profit / (loss) and other comprehensive income for the period) (XIII + XIV)</b>	<b>342.22</b>	<b>489.18</b>	<b>186.80</b>	<b>1,078.16</b>	<b>788.71</b>	<b>1,133.41</b>
XVI	Paid up Equity share capital (Face value of Rs. 10 each)	1,230.46	1,230.46	1,230.46	1,230.46	1,230.46	1,230.46
XVII	Reserves & Surplus excluding revaluation reserve	6,971.53	6,629.31	5,545.97	6,971.53	5,545.97	5,893.37
XVIII	Earnings per equity share (for discontinued operation)						
	(1) Basic	0.00	0.00	0.00	0.00	0.00	0.00
	(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00
XIV	Earnings per equity share (for discontinued & continuing operation) (EPS for 3 and 9 months ended periods are not annualised)						
	(1) Basic	2.78	3.97	1.52	8.76	6.41	9.21
	(2) Diluted	2.78	3.97	1.52	8.76	6.41	9.21


For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited

Mr. Jigneshbhai V. Savani  
Director & CEO  
(DIN - 00198203)



For and on behalf of Board of Directors  
Par Drugs and Chemicals Limited

Mr. Jagan V. Savani  
(Chairman & Managing Director)  
(DIN - 00198236)



# **PAR DRUGS AND CHEMICALS LIMITED**

(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road,  
Vadodara-390007, Gujarat, India



Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com

Website: www.pardrugs.com

---

## **NOTES:**

1. The standalone financial results of the Company have been prepared in accordance with the Ind AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, other accounting principles generally accepted in India and in term of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, including relevant circulars issued by the SEBI from time to time.
2. The above quarterly and year to date financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 16<sup>th</sup> February, 2024.
3. The Statutory auditors of the company have carried out Limited Review of the above quarterly & nine month ended financial results as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015.
4. The weighted average number of equity shares outstanding during the period has been considered for calculating the basic and diluted earning per share (not annualized) in accordance with the Ind AS.
5. Previous Year/Period figures are regrouped / reclassified / rearranged, whenever found necessary to make them comparable with the current period figures.
6. The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on "Operating Segments". Accordingly, there are no separate reportable segments as per Ind AS - 108.
7. The Company does not have any subsidiary, associates or joint venture as on 31<sup>st</sup> December, 2023; therefore, it has prepared only standalone results as consolidation requirement is not applicable to the Company.



# **PAR DRUGS AND CHEMICALS LIMITED**

(CIN : L24117GJ1999PLC035512)

Registered Office : 815, Nilamber Triumph, Gotri Vasna Road,  
Vadodara-390007, Gujarat, India

Phone No. +91-265-2991020/2991022, Email: admin@pardrugs.com

Website: www.pardrugs.com

8. The above unaudited financial results of the Company are available on the Company's website – www.pardrugs.com and on the website of the National Stock Exchange of India Limited (www.nseindia.com), where the Company's shares are listed.

9. The Status of investors complaints are as follows:

I. Pending at the beginning of the quarter	-	0
II. Received during the quarter	-	0
III. Disposed-off during the quarter	-	0
IV. Remaining unresolved at the end of the quarter	-	0


For and on behalf of Board of Directors

Par Drugs and Chemicals Limited

Mr. Falgun V Savani

(Chairman & Managing Director)

(DIN - 00198236)




For and on behalf of Board of Directors

Par Drugs and Chemicals Limited

Mr. Jigneshbhai V Savani

(Director & CEO)

(DIN - 00198203)



Bhavnagar, 16<sup>th</sup> February, 2024

To,  
The Board of Directors  
Par Drugs And Chemicals Limited


## CERTIFICATE OF CORRECTNESS OF FINANCIAL RESULTS

Pursuant to Regulation 33(2)(a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby certify that the financial results of the Company for quarter and nine months ended on 31<sup>st</sup> December, 2023 placed before the meeting, do not contain any false or misleading statement or figures and do not omit any material fact which may make the statements or figures contained therein misleading


**For Par Drugs And Chemicals Limited**

Date: 16/02/2024


Place: Bhavnagar



(Mr. Jignesh V. Savani)  
Chief Executive Officer



**For Par Drugs And Chemicals Limited**



(Mr. Chintan P. Chauhan)  
Chief Financial Officer

